ENDING THE OPIOID CRISIS
BY THE NUMBERS
There are over 81,000 opioid overdose deaths in the United States last year, according to the CDC. That's an average of 221 opioid overdose deaths per day.
Over 10 million Americans misuse prescription opioids each year, according to the most recent data from the HHS.
The CDC estimates that the economic impact of the opioid crisis is $79 Billion in lost productivity, medical, and rehabilitation services,
We started out as college friends looking for a purpose in our lives and a way to make a difference in the world around us. We were touched by lives torn apart from drug addiction and the massive opioid epidemic ravaging our country, and we knew that we had to do something about it. So, we founded Runatek to develop a medical device that can prevent opioid addictions in the first place. Our purpose is to save lives with this ground-breaking technology.
Our mission is simple: End the Opioid Crisis.
We're developing a wearable IV pump that monitors the concentrations of prescription opioid medication in the bloodstream. The device uses a measurement of the patient’s body mass and the doctor’s prescription to set a proper blood concentration level for the patient to achieve pain relief without experiencing a potentially addicting “high.” The device automatically administers intravenous (IV) opioid medications to maintain this prescribed concentration without the possibility of misuse.
INTRODUCING THE SOTIRAS
INVEST IN THE FUTURE OF MEDICINE
We are seeking keen investors to join our team and help take us to the next level. We will be launching a VC round in 2021 to raise capital to get our technology through the FDA approvals process.
As with any investment, there is a certain degree of risk. We do everything that we can to protect and grow the investment through smart management practices. We strive to be open and transparent about the operations and direction of our organization, so that investors can make confident investment decisions. Our investors receive regular updates on the performance of the company and are a key part of our decision process during annual meetings.
We're an early-stage startup, and we're attracting top-notch talent to our growing team of over a dozen dedicated individuals. Our team members come from a variety of backgrounds, but we all share the same goal: to end the opioid crisis.